Use of .delta.5-androstene-3.beta.-ol-7,17-dione in the treatment of arthritis
CA 2311471 A1 · Owner: Humanetics Corporation · Inventors: Weeks, Charles E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Arthritis can be treated by administering therapeutic amounts of .DELTA.5androstene-3.beta.-ol-7,17-dione and metabolizable precursors thereof such as , .DELTA.5-androstene-3.beta.-acetoxy-7,17-dione which are readily metabolized , in vivo to .DELTA.5-androstene-3.beta.-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 17, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 17, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 17, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.